越洋医药首页

Optimize People's Lives

关于我们

越洋医药依托自主控释技术，专注于 505(b)(2) 路径下创新药物研发，延长既有产品专利保护，并提升新化合物的成药性。

通过聚焦产品组合管理，我们持续提升药效、降低不良反应、改善患者依从性、延展知识产权保护，并打造差异化产品。

从创新研发到商业化，我们在口服固体控释技术方面积累了系统能力，并正在拓展口服多肽递送等新平台，为临床和商业化提供高性能解决方案。

公司创立于 2011 年，在美国圣地亚哥、中国广州和台州设有基地，拥有约 150,000 平方英尺的研发、中试和 GMP 生产设施，并具备受控物质相关 DEA 与 FDA 许可。

我们的技术

我们的技术

经过多年积累，越洋医药建立了零级释放、脉冲释放、缓释、延释、迟释以及组合释放等专有技术。这些技术可将既有速释产品转化为控释新药，降低新化合物不良反应并改善患者依从性。核心平台技术包括：

  • UC-Trol®
  • Mech-Trol®
  • Dual-Trol®
  • Dual-Release®
  • G-Trol®
品牌故事

品牌故事

越洋医药结合制剂科学、临床洞察和全球注册经验，推进差异化治疗方案。

我们的团队

我们的团队

核心团队拥有数十年跨国药企药物研发经验，曾任职于 GSK、Pfizer、Abbvie、AZ 和 Mylan 等企业，并推动多个新药成功获批和上市。我们为合作伙伴提供专业能力、战略洞察和创新成果转化经验。

核心适应症

核心适应症

  • 疼痛管理
  • 失眠
  • 心血管疾病
  • 中枢神经系统
  • 自身免疫疾病
51+FDA 批准 IND
20+专利
2+III 期临床试验
13+I 期临床试验

我们的技术

技术已通过人体 PK 曲线验证。
技术 PK 曲线 1
技术 PK 曲线 2
技术 PK 曲线 3
技术 PK 曲线 4
技术 PK 曲线 5
技术 PK 曲线 6
技术 PK 曲线 7
技术 PK 曲线 8

产品管线

不同治疗领域和临床阶段的产品管线

Category Product Indication Pre-clinical IND Phase I Phase III
疼痛管理
OPL-015 General Pain
OPL-054 General pain
OPL-055 General pain
OPL-056 General pain
OPL-004 General pain
OPL-053 Pain-induced insomnia
OPL-022 Morning surge
心血管疾病
OPL-009 Morning surge
OPL-034 Venous thrombosis
OPL-085 Heart Failure
中枢神经系统
OPL-032 Insomnia
OPL-026 Epilepsy
OPL-044 Epilepsy
OPL-020 Depression
自身免疫疾病
OPL-042 OA
OPL-029 OA
OPL-040 IPF
糖尿病
OPL-025 Diabetes
OPL-028 Diabetes

我们的团队

办公地点

我们的美国公司办公室和研发中心位于圣地亚哥，中国公司办公室和研发基地位于台州，并在广州设有符合 GMP 要求的商业化生产设施。

联系我们

产品

FDA 批准

FDA 批准

NMPA 批准

NMPA 批准

MFDS 批准

MFDS 批准

设备能力

Capability equipment
OPL team moment
OPL team activity OPL colleagues

How We Work

Find a Way Forward

We are resourceful, resilient, and solution-oriented. Obstacles are opportunities to innovate.

Execute with Excellence

We maintain high standards, move with purpose, and deliver on our commitments.

加入我们

在越洋医药，创新始于人才。

我们期待热爱药物研发、工程技术和专业运营的人才加入，共同推动药物开发并改善患者获益。依托世界级设备、专有药物递送技术和协作文化，越洋医药为员工提供持续学习、成长和创造长期价值的机会。

成就职业发展    推动创新突破    改善患者生活

General Manager, U.S. Formulation CRO Subsidiary

Oversee all local operations, source formulation development clients whose projects are initially executed by China headquarters, and build local capabilities to independently deliver R&D projects long-term.

Contact Email: contact@oplpharma.com

General Manager, U.S. Formulation CRO Subsidiary

Oversee all local operations, source formulation development clients whose projects are initially executed by China headquarters, and build local capabilities to independently deliver R&D projects long-term.

Contact Email: contact@oplpharma.com

加入我们
OPL team OPL team

合作伙伴

01

Product Licensing

OPL offers licensing opportunities for both innovative and generic pharmaceutical products.

Innovative Drug Products

Available for licensing at various stages of development, including:

  • IND-ready, phase I to phase III programs
  • Clinical pharmacokinetic (PK) stage programs with target PK profiles achieved
  • Clinical efficacy stage programs that have met primary and secondary study endpoints
Product LicensingOPL offers licensing opportunities for both innovative and generic pharmaceutical products.
02

Proprietary Timed-Release Technologies

OPL's advanced drug delivery platforms enable pharmaceutical companies to enhance product performance and extend product lifecycles.

Product Lifecycle Extension

  • Conversion of immediate-release (IR) products into controlled-release (CR) formulations
  • Development of differentiated, next-generation products
  • Strong platform IP protection

New Chemical Entity (NCE) formulation enhancement

Our technologies can help:

  • Reduce dosing frequency
  • Improve patient compliance
  • Minimize peak-to-trough plasma concentration fluctuations
  • Reduce dose-related adverse effects
  • Enhance overall product performance
Proprietary Timed-Release TechnologiesOPL's advanced drug delivery platforms enable pharmaceutical companies to enhance product performance and extend product lifecycles.
03

Generic Product Differentiation

Alternative formulation technologies for ANDA development.

  • Patent circumvention for first-to-file opportunities
  • Controlled-release platform solutions for complex generic products
  • Product differentiation strategies in competitive markets
Generic Product DifferentiationAlternative formulation technologies for ANDA development.
04

Strategic Partnerships

We collaborate with a wide range of pharmaceutical and healthcare organizations.

Our flexible partnership models support licensing, co-development, technology transfer, and commercialization initiatives.

  • Contract Manufacturing Organizations (CMOs)
  • Specialty pharmaceutical companies
  • Multinational pharmaceutical companies
  • Generic pharmaceutical manufacturers
  • Emerging biotech and specialty drug developers
Strategic PartnershipsWe collaborate with a wide range of pharmaceutical and healthcare organizations.
05

Formulation Development & CMC Services

IND-enabling formulation development to support emerging biotech and small-molecule innovators.

  • Preclinical formulation development
  • IND-enabling studies
  • Clinical trial material manufacturing
  • Phase I, Phase II, and Phase III clinical development support
Formulation Development & CMC ServicesIND-enabling formulation development to support emerging biotech and small-molecule innovators.

联系我们

为什么选择与 OPL 合作？

  • 在定时释放药物递送技术方面拥有成熟专业能力
  • 具备支持 505(b)(2)、NDA、IND 和 ANDA 项目的经验
  • 覆盖研发、临床开发、注册支持和 GMP 生产的一体化能力
  • 面向授权、共同开发和合同服务的灵活合作模式
  • 美国和中国的全球运营布局，支持高效产品开发和商业化

OPL Pharmaceuticals

Address: 6323 Nancy Ridge Drive, San Diego,
California USA 92121

Email: bryce_babcock@oplpharm.com

Phone: (+1) 650-388-9210

联系我们

你可以通过电话或填写下方表单与我们联系，我们的工作人员会及时处理你的咨询。

点击刷新验证码
首页
产品
新闻
联系